Search clinical trials for: Relapsed Lymphoma

Total 13593 results

Miltenyi Biomedicine GmbH

Recruiting

DALY II USA/ MB-CART2019.1 for DLBCL

Central Nervous System Lymphoma | Transformed Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL) | Relapsed Diffuse Large B Cell Lymphoma

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

B-ALL

China
Bambino Gesù Hospital and Research Institute

Recruiting

CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML

Acute Lymphoblastic Leukemia | Diffuse Large B Cell Lymphoma | Primary Mediastinal Lymphoma

Italy
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma

China
Newave Pharmaceutical Inc

Recruiting

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Hairy Cell Leukemia | CLL/SLL

United States
Grupo Argentino de Tratamiento de la Leucemia Aguda
Takeda

Recruiting

RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT

Refractory Hodgkin Lymphoma | Hodgkin Lymphoma, Adult | Relapsed Hodgkin's Disease, Adult

Argentina
Newave Pharmaceutical Inc

Recruiting

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Small Lymphocytic Lymphoma | Chronic Myelomonocytic Leukemia-2 | Richter Transformation | T-cell-prolymphocytic Leukemia and other conditions

United States
Huazhong University of Science and Technology
Shanghai IASO Biotechnology Co., Ltd

Not yet recruiting

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Peripheral T-cell Lymphomas (PTCL) | CD5+ Relapsed/Refractory Hematopoietic Malignancies | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL)
NovalGen Ltd.

Recruiting

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Non-small Cell Lung Cancer (NSCLC) | Small Lymphocytic Lymphoma | Malignant Melanoma | Chronic Lymphocytic Leukaemia

United Kingdom
Won Seog Kim
Sanofi

Recruiting

Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy (ICING)

Natural Killer/T-cell Lymphoma | Relapsed Natural Killer/T-cell Lymphoma | Refractory Natural Killer/T-cell Lymphoma

Korea, Republic of
C4 Therapeutics, Inc.

Recruiting

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Multiple Myeloma | Lymphoma, Non-Hodgkin's

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Lymphoma | Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma

United States
Benjamin Tomlinson

Recruiting

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Kronos Bio

Recruiting

A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma | Refractory Solid Tumors | Relapsed Solid Tumors

United States, Spain, United Kingdom
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Shanxi Province Cancer Hospital
Shanghai Ultra-T Immune Therapeutics Co. LTD

Recruiting

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

Acute Lymphocytic Leukemia， B-Cell

China
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (Celestimo)

Relapsed or Refractory Follicular Lymphoma

United States, Korea, Republic of, Taiwan, China, Spain, United Kingdom, Australia, France, Germany, Japan, Turkey, Brazil, Poland, Ukraine, Italy, Russian Federation
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

PTCL
Han weidong

Recruiting

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma | Decitabine-primed Tandem CD19/CD20 CAR T Cells

China
Beijing Boren Hospital

Recruiting

Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma

Relapse/Recurrence | T-cell Leukemia/Lymphoma | Refractory T Lymphoblastic Leukemia/Lymphoma

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
PeproMene Bio, Inc.
City of Hope Medical Center

Recruiting

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

United States
Liqun Zou

Recruiting

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Leukemia

China
Juventas Cell Therapy Ltd.

Recruiting

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Relapsed or Refractory Acute Lymphoblastic Leukemia

China
Jacob Soumerai, MD
GlaxoSmithKline

Recruiting

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Relapsed Plasmablastic Lymphoma | Refractory Plasmablastic Lymphoma | Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma

United States
Artiva Biotherapeutics, Inc.

Recruiting

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Peripheral T Cell Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Non-hodgkin's Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

China
Qian Wenbin

Not yet recruiting

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

China
Fundació Institut de Recerca de l'Hospital de la...
Instituto de Salud Carlos III; Josep Carreras Leukaemia Research Institute

Recruiting

CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.

Hodgkin Lymphoma, Adult | T Cell Lymphoma

Spain
Sabz Biomedicals
Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical... and other collaborators

Not yet recruiting

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL) | Refractory B Cell Acute Lymphoblastic Leukemia (ALL)

Iran, Islamic Republic of
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Non-Hodgkin Lymphoma | Refractory Histiocytic and Dendritic Cell Neoplasm | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma

United States
Caribou Biosciences, Inc.

Recruiting

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Lymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's Lymphoma

United States, Australia, Israel
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Hebei Senlang Biotechnology Inc., Ltd.
The Second Hospital of Hebei Medical University

Recruiting

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Refractory Indolent Adult Non-Hodgkin Lymphoma

China
Sun Yat-sen University

Recruiting

PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

Classical Hodgkin Lymphoma | Refractory or Relapsed Classical Hodgkin Lymphoma

China
Genmab
AbbVie

Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

Small Lymphocytic Lymphoma | Richter's Syndrome | Relapsed/Refractory Chronic Lymphocytic Leukemia

United States, Belgium, Netherlands, Spain, Italy, Australia, Israel, France, Denmark, Czechia, Germany, United Kingdom
Celgene

Recruiting

Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

Lymphoma Nonhodgkin

Japan
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Lymphoma | Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

Relapsed and/or Refractory Acute Lymphoblastic Leukemia | Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma

China
National Taiwan University Hospital

Not yet recruiting

Lenalidomide and Low-dose Cyclophosphamide for MALT Lymphoma (LCMALT)

Antibiotics-unresponsive MALT Lymphoma | Relapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma | Refractory Extranodal Marginal Zone B-Cell Lymphoma (MALT)

Taiwan
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
Taizhou HoudeAoke Biomedical Co., Ltd.

Not yet recruiting

Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

CD7+ Acute Leukemia | CD7+ Lymphoma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (CD5CAR-T)

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma

China

Search clinical trials for: Relapsed Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations